1. Home
  2. LEXX vs GFAI Comparison

LEXX vs GFAI Comparison

Compare LEXX & GFAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEXX
  • GFAI
  • Stock Information
  • Founded
  • LEXX 2004
  • GFAI 2018
  • Country
  • LEXX Canada
  • GFAI Singapore
  • Employees
  • LEXX N/A
  • GFAI N/A
  • Industry
  • LEXX Biotechnology: Pharmaceutical Preparations
  • GFAI Diversified Commercial Services
  • Sector
  • LEXX Health Care
  • GFAI Consumer Discretionary
  • Exchange
  • LEXX Nasdaq
  • GFAI Nasdaq
  • Market Cap
  • LEXX 22.7M
  • GFAI 19.1M
  • IPO Year
  • LEXX N/A
  • GFAI N/A
  • Fundamental
  • Price
  • LEXX $1.13
  • GFAI $0.77
  • Analyst Decision
  • LEXX Strong Buy
  • GFAI Strong Buy
  • Analyst Count
  • LEXX 1
  • GFAI 1
  • Target Price
  • LEXX $4.00
  • GFAI $4.50
  • AVG Volume (30 Days)
  • LEXX 212.4K
  • GFAI 429.8K
  • Earning Date
  • LEXX 01-09-2026
  • GFAI 09-23-2025
  • Dividend Yield
  • LEXX N/A
  • GFAI N/A
  • EPS Growth
  • LEXX N/A
  • GFAI N/A
  • EPS
  • LEXX N/A
  • GFAI N/A
  • Revenue
  • LEXX $615,923.00
  • GFAI $36,987,715.00
  • Revenue This Year
  • LEXX $46.98
  • GFAI $5.66
  • Revenue Next Year
  • LEXX $17.26
  • GFAI $4.69
  • P/E Ratio
  • LEXX N/A
  • GFAI N/A
  • Revenue Growth
  • LEXX 49.85
  • GFAI 4.38
  • 52 Week Low
  • LEXX $0.77
  • GFAI $0.58
  • 52 Week High
  • LEXX $2.85
  • GFAI $3.88
  • Technical
  • Relative Strength Index (RSI)
  • LEXX 57.12
  • GFAI 41.80
  • Support Level
  • LEXX $1.00
  • GFAI $0.58
  • Resistance Level
  • LEXX $1.19
  • GFAI $0.93
  • Average True Range (ATR)
  • LEXX 0.08
  • GFAI 0.07
  • MACD
  • LEXX -0.00
  • GFAI -0.00
  • Stochastic Oscillator
  • LEXX 66.25
  • GFAI 56.19

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

About GFAI Guardforce AI Co. Limited

Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, General Security Solutions, and Corporate and others. A majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions.

Share on Social Networks: